Simultaneous absolute quantification of the glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 in mouse plasma by LC/ESI-MS/MS: Preclinical evaluation of DP-IV inhibitors

Journal of Proteome Research

Volumn 8, Issue 7, 2009, Pages 3487-3496

  Siskos, Alexandros P ^a   Katsila, Theodora ^a   Balafas, Evangelos ^a   Kostomitsopoulos, Nikolaos ^a   Tamvakopoulos, Constantin ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Biomarker verification validation; Glucose dependent insulinotropic polypeptide; Incretin hormones; LC ESI MS MS; Liquid chromatography; Peptide pharmacokinetics; Polypeptide absolute quantification; Tandem mass spectrometry

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE1 42; GASTRIC INHIBITORY POLYPEPTIDE3 42; INCRETIN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN SYNTHESIS;

ANIMALS; ANTIGENS, CD26; BIOLOGICAL MARKERS; BUFFERS; CHROMATOGRAPHY, LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; GLUCOSE; HUMANS; INSULIN; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; PEPTIDES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

MUS;

EID: 67650360365     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900155h     Document Type: Article

References (52)

1. Deacon, C. F. Circulation and degradation of GIP and GLP-1. Review. Horm. Metab. Res. 2004, 36, 761-765.
2. McIntosh, C. H. S.; Demuth, H. U.; Kim, S. J.; Pospisilik, J. A.; Pederson, R. A. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Review. Int. J. Biochem. Cell Biol. 2006, 38, 860-872.
3. Weber, A. E. Dipetidyl Peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 2004, 47, 4135-4141.
4. Herman, G. A.; Stein, P. P.; Thornberry, N. A.; Wagner, J. A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther. 2007, 81 (5), 761-767.
5. Krishna, R.; Herman, G.; Wagner, J. A. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J. 2008, 10 (2), 401-409.
6. Deacon, C. F.; Nauck, M. A.; Meier, J.; Hücking, K.; Holst, J. J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000, 85 (10), 3575-3581.
7. Meier, J. J.; Gethmann, A.; Nauck, M. A.; Götze, O.; Schmitz, F.; Deacon, C. F.; Gallwitz, B.; Schmidt, W. E.; Holst, J. J. The glucagonlike peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab. 2006, 290 (6), E1118-1123.
8. Copley, K.; McCowen, K.; Hiles, R.; Nielsen, L. L.; Young, A.; Parkes, D. G. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr. Drug Metab. 2006, 7 (4), 367-374.
9. Ding, K. H.; Zhong, Q.; Xie, D.; Chen, H. X.; Della-Fera, M. A.; Bollag, R. J.; Bollag, W. B.; Gujral, R.; Kang, B.; Sridhar, S.; Baile, C.; Curl, W.; Isales, C. M. Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 2006, 27 (11), 2750-2755.
10. 3-42 from human plasma samples; New sensitive method to analyze physiological concentrations of peptide hormones. J. Chromatogr., A 2001, 926, 21-27.
11. Wolf, R.; Hoffmann, T.; Rosche, F.; Demuth, H. U. Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. J. Chromatogr., B 2004, 803, 91-99.
12. Theodorakis, M. J.; Muller, D. C.; Carlson, O.; Egan, J. M. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004, 27, 1692-1698.
13. Zhu, L.; Tamvakopoulos, C.; Xie, D.; Dragovic, J.; Shen, X.; Fenyk-Melody, J. E.; Schmidt, K.; Bagchi, A.; Griffin, P. R.; Thornberry, N. A.; Roy, R. S. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides. J. Biol. Chem. 2003, 278 (25), 22418-22423.
14. Yang, Z.; Hayes, M.; Fang, X.; Daley, M. P.; Ettenberg, S.; Tse, F. L. S. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid phase extraction cleanup. Anal. Chem. 2007, 79, 9294-9301.
15. Carr, S. A.; Anderson, L. Protein quantification through targeted mass spectrometry: the way out of biomarker purgatory. Clin. Chem. 2008, 54 (11), 1749-1752.
16. Bakhtiar, R.; Guan, Z. Electron capture dissociation mass spectrometry in characterization of peptides and proteins. Biotechnol. Lett. 2006, 28 (14), 1047-1059.
17. Tamvakopoulos, C. Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom. Rev. 2007, 26 (3), 389-402.
18. Anderson, N. L.; Anderson, N. G. The human plasma proteome; history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1 (11), 845-867.
19. MacCoss, M. J.; Matthews, D. E. Quantitative MS for proteomics: teaching a new dog old tricks. Anal. Chem. 2005, 77 (15), 294A-302A.
20. Garbis, S. D.; Tyritzis, S. I.; Roumeliotis, T.; Zerefos, P.; Giannopoulou, E. G.; Vlahou, A.; Kossida, S.; Diaz, J.; Vourekas, S.; Tamvakopoulos, C.; Pavlakis, K.; Sanoudou, D.; Constantinides, C. A. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using aminespecific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2008, 7 (8), 3146-3158.
21. Kulasingam, V.; Diamandis, E. P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5 (10), 588-599.
22. Kirkpatrick, D. S.; Gerber, S. A.; Gygi, S. P. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35, 265-273.
23. Heudi, O.; Barteau, S.; Zimmer, D.; Schmidt, J.; Bill, K.; Lehmann, N.; Bauer, C.; Kretz, O. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 2008, 80, 4200-4207.
24. Elbert, D. L.; Mawuenyega, K. G.; Scott, E. A.; Wildsmith, K. R.; Bateman, R. J. Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans. J. Proteome Res. 2008, 7, 4546-4556.
25. Arsene, C. G.; Ohlendorf, R.; Burkitt, W.; Pritchard, C.; Henrion, A.; O'Connor, G.; Bunk, D. M.; Guttler, B. Protein quantification by isotope dilution mass spectrometry of proteolytic fragments: cleavage rate and accuracy. Anal. Chem. 2008, 80, 4154-4160.
26. Bateman, R. J.; Munsell, L. Y.; Chen, X.; Holtzman, D. M.; Yarasheski, K. E. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J. Am. Soc. Mass Spectrom. 2007, 18 (6), 997-1006.
27. Dupuis, A.; Hennekinne, J. A.; Garin, J.; Brun, V. Protein Standard Absolute Quantification (PSAQ) for improved investigation of staphylococcal food poisoning outbreaks. Proteomics 2008, 8, 4633-4636.
28. John, H.; Walden, M.; Schäfer, S.; Genz, S.; Forssmann, W. G. Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 2004, 378 (4), 883-897.
29. Pan, S.; Aebersold, R.; Chen, R.; Rush, J.; Goodlett, D. R.; McIntosh, M. W.; Zhang, J.; Brentnall, T. A. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 2009, 8 (2), 787-797.
30. Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S. A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2007, 6 (12), 2212-2229.
31. van den Broek, I.; Sparidans, R. W.; Schellens, J. H.; Beijnen, J. H. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr., B 2008, 872, 1-22.
32. Wan, H.; Umstot, E. S.; Szeto, H. H.; Schiller, P. W.; Desiderio, D. M. Quantitative analysis of [Dmt1]DALDA in ovine plasma by capillary liquid chromatography-nanospray ion-trap mass spectrometry. J. Chromatogr., B 2004, 803, 83-90.
33. Szeto, H. H.; Lovelace, J. L.; Fridland, G.; Soong, Y.; Fasolo, J.; Wu, D.; Desiderio, D. M.; Sciller, P. W. In vivo pharmacokinetics of selective μ-opioid peptide agonists. J. Pharmacol. Exp. Ther. 2001, 298, 57-61.
34. Hatziieremia, S.; Kostomitsopoulos, N.; Balafas, V.; Tamvakopoulos, C. A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Rapid Commun. Mass Spectrom. 2007, 21, 2431-2438.
35. Sofianos, Z. D.; Katsila, T.; Kostomitsopoulos, N.; Balafas, V.; Matsoukas, J.; Tselios, T.; Tamvakopoulos, C. Pharmacokinetics and In Vitro metabolism of leuprolide in mice - mass spectrometry based evaluation of efficacy and toxicity. J. Mass Spectrom. 2008, 43, 1381-1392.
36. van den Broek, I.; Sparidans, R. W.; Schellens, J. H.; Beijnen, J. H. Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Commun. Mass Spectrom. 2008, 22 (18), 2915-2928.
37. Becher, F.; Pruvost, A.; Clement, G.; Tabet, J. C.; Ezan, E. Quantification of small therapeutic proteins in plasma by liquid chromatography tandem mass spectrometry: application to an lestase inhibitor EPI-hNE4. Anal. Chem. 2006, 78 (7), 2306-2313.
38. Dass, C.; Kusmierz, J. J.; Desiderio, D. M. Mass Spectrometric Quantification of Endogenous β-Endorphin. Biol. Mass Spectrom. 1991, 20, 130-138.
39. van den Broek, I.; Sparidans, R. W.; Schellens, J. H. M.; Beijnen, J. H. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: Measurement of chymotrypsin fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. J. Chromatogr., B 2007, 854, 245-259.
40. Kuhn, E.; Wu, J.; Karl, J.; Liao, H.; Zolg, W.; Guild, B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labelled peptide standards. Proteomics 2004, 4, 1175-1186.
41. Barnidge, D. R.; Goodmanson, M. K.; Klee, G. G.; Muddiman, D. C. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 2004, 3, 644-652.
42. Kay, R.; Barton, C.; Ratcliffe, L.; Matharoo-Ball, B.; Brown, P.; Roberts, J.; Teale, P.; Creaser, C. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun. Mass Spectrom. 2008, 22, 3255-3260.
43. Dubois, M.; Becher, F.; Herbet, A.; Ezan, E. Immuno-mass spectrometry assay of EPI-hNE4, a recombinant protein inhibitor of human elastase. Rapid Commun. Mass Spectrom. 2007, 21, 352-358.
44. Becher, F.; Duriez, E.; Volland, H.; Tabet, J. C.; Ezan, E. Detection of functional ricin by immunoaffinity and liquid chromatographytandem mass spectrometry. Anal. Chem. 2007, 79 (2), 659-665.
45. Anderson, N. L.; Anderson, N. G.; Haines, L. R.; Hardie, D. B.; Olafson, R. W.; Pearson, T. W. Mass spectrometric quantification of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 2004, 3, 235-244.
46. Berna, M. J.; Zhen, Y.; Watson, D. E.; Hale, J. E.; Ackermann, B. L. Strategic use of immunoprecipitation and LC/MS/MS for trace level protein quantification: myosin light chain 1, a biomarker of cardiac necrosis. Anal. Chem. 2007, 79 (11), 4199-4205.
47. Berna, M.; Ott, L.; Engle, S.; Watson, D.; Solter, P.; Ackermann, B. Quantification of NTproBNP in rat serum using immunoprecipitation and LC/MS/MS: a biomarker of drug-induced cardiac hypertrophy. Anal. Chem. 2008, 80 (3), 561-566.
48. Kulasingam, V.; Smith, C. R.; Batruch, I.; Buckler, A.; Jeffery, D. A.; Diamandis, E. P. "Product ion monitoring" assay for prostatespecific antigen in serum using a linear ion-trap. J. Proteome Res. 2008, 7 (2), 640-647.
49. Dubois, M.; Fenaille, F.; Clement, G.; Lechmann, M.; Tabet, J. C.; Ezan, E.; Becher, F. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal. Chem. 2008, 80 (5), 1737-1745.
50. Appels, N. M. G. M.; Rosing, H.; Stephens, T. C.; Hughes, A.; Schellens, J. H. M.; Beijnen, J. H. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. Anal. Biochem. 2006, 352, 33-40.
51. Sharpless, N. E.; Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discovery 2006, 5 (9), 741-754.
52. Polson, C.; Sarkar, P.; Incledon, B.; Raguvaran, V.; Grant, R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatographytandem mass spectrometry. J. Chromatogr., B 2003, 785, 263-275.